Kelly Financial Services LLC Biogen Inc. Transaction History

Kelly Financial Services LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Jul 17, 2024	SELL	$282.99 - $369.05 $55.1 Million - $71.9 Million	-194,718 Reduced 99.71%	564 $160 Million
Q2 2021 Jul 17, 2024	BUY	$259.0 - $414.71 $49.3 Million - $79 Million	190,518 Added 3999.12%	195,282 $564,000
Q1 2021 Jul 17, 2024	BUY	$242.95 - $284.63 $68,511 - $80,265	282 Added 6.29%	4,764 $1.33 Billion
Q2 2020 Jul 17, 2024	BUY	$258.66 - $342.55 $2,845 - $3,768	11 Added 0.25%	4,482 $1.2 Billion
Q4 2019 Jul 17, 2024	BUY	$220.06 - $304.07 $8,362 - $11,554	38 Added 0.86%	4,471 $1.33 Billion
Q3 2019 Jul 17, 2024	BUY	$217.44 - $243.88 $1,087 - $1,219	5 Added 0.11%	4,433 $1.03 Billion
Q1 2019 Jul 17, 2024	BUY	$216.71 - $338.96 $959,591 - $1.5 Million	4,428 New	4,428 $1.05 Billion

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Kelly Financial Services LLC, based on Form 13F filings with the SEC.

Stay updated on Kelly Financial Services LLC with notifications on news.